Administrative Court Error Complicates Infarmed Vaccine Data Transparency

By João L. Carapinha

February 23, 2026

Court Clerical Error Threatens Infarmed Vaccine Data Transparency

Infarmed vaccine data transparency hangs in the balance due to a clerical error by the Lisbon Administrative Court’s secretariat, which sent a January 16 dispatch from Judge Ana de Campos to PÁGINA UM’s former lawyer. This misstep interpreted the outlet’s silence on Infarmed’s compliance with a data release order as implicit confirmation, potentially allowing Infarmed to evade full disclosure of COVID-19 vaccine pharmacovigilance data. Despite PÁGINA UM’s prompt reply, the judge may deem the matter moot, extending litigation and highlighting delays in accessing adverse reaction reports from vaccines and Remdesivir.

Gaps in Released Vaccine Data

Partial pharmacovigilance data from Infarmed, released in August 2024 and covering only December 2020 to December 2021, reveals critical omissions like causality grading, dose numbers, batch details, age, municipality, and notifier profession. Of 27,220 adverse reactions, 7,110 were serious, including 104 deaths—such as an 80+ year-old woman dying two minutes after Pfizer vaccination and a man from pulmonary thromboembolism 15 minutes post-dose. Under-25s saw 513 serious reactions (225 without follow-up), plus nine deaths in the 25-49 group. Broader Portal RAM data to August 2024 showed 19,224 of 45,337 entries (42.4%) with “unknown” outcomes, including myocarditis/pericarditis, anaphylaxis, embolisms, Guillain-Barré, strokes, thromboses, and infarctions.

PÁGINA UM’s December 6, 2021, request for Remdesivir and COVID-19 vaccine data was denied by Infarmed under Rui Santos Ivo, leading to the Commission on Access to Administrative Documents. On March 16, 2022, it ordered anonymized release, rejecting refusals. Infarmed’s non-compliance triggered summons, a March 2023 overturned ruling, and a July 11, 2024, Tribunal Central Administrativo do Sul order for full data. Infarmed’s truncated response prompted PÁGINA UM’s July 2024 fine request (€200 minimum daily on Ivo).

Reference url

Recent Posts

Substandard Medicines in South Africa: Regulatory Challenges and Economic Implications

By HEOR Staff Writer

May 21, 2026

Substandard medicines in South Africa continue to infiltrate supply chains through informal markets, unlicensed outlets, and online platforms, leaving patients exposed to unregulated weight-loss injections amid stock shortages and high costs for approved options such as Ozempic. Comp...
First-in-Human Trials: Foundations and Market Implications in Health Economics

By HEOR Staff Writer

First-in-Human Trials mark the initial transition of a drug candidate from extensive preclinical research into human subjects, supplying the earliest clinical evidence on safety, pharmacokinetics, and pharmacodynamics to inform later development stages. These studies rely on a comprehensive found...
Transforming Healthcare Value: Strategic Purchasing in South Africa

By João L. Carapinha

May 20, 2026

Strategic Purchasing Healthcare offers a pathway for South Africa’s healthcare system to deliver improved patient outcomes amid constrained resources, where traditional passive purchasing models relying on historical budgets or uncapped fee-for-service payments have fallen short in prioritising e...